Optimization of a combined therapeutic drug monitoring – pharmacogenetic (TDMPG) approach to explain subtherapeutic, therapeutic and supratherapeutic concentrations of neuropsychopharmacologic medications

We are optimizing a combined therapeutic drug monitoring – pharmacogenetic (TDMPG) approach to explain why patients at psychiatric inpatient wards show neuropsychopharmacologic medication blood plasma concentrations (plasma levels) below, within, or above the orienting therapeutic range (OTR).